Recent Updates
Recently added Catalysts
VYGR Positive Sentiment

Voyager Reports Second Quarter 2026 Financial and Operating Results

Thursday, August 6, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Voyager Therapeutics reported its second quarter 2026 financial results, highlighting the expected clinical data for VY7523 and VY1706 in Alzheimer's by Q4 2026. The company ended the quarter with a robust cash position of $149 million, providing a financial runway into 2028. This positions Voyager favorably for ongoing and future developments.

Market Sentiment Analysis

POSITIVE FACTORS

  • VY7523 and VY1706 are advancing in clinical trials for Alzheimer's.
  • Company has a strong cash position of $149 million.
  • Financial runway extends into 2028, indicating stability.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~12 mo
Low dilution risk
Lead asset
VP4896
Phase 3 · Alzheimer's Disease

Full Press Release Details

- VY7523 clinical data and VY1706 clinical entry, both in Alzheimer’s, expected Q4 2026 - - Ended Q2 2026 with cash position of $149 million, runway into 2028 - LEXINGTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to

Frequently Asked Questions

What are the key highlights from Voyager's Q2 2026 report?

Voyager reported a cash position of $149 million and plans to present clinical data for VY7523 and VY1706 in Q4 2026.

What is the financial runway for Voyager Therapeutics?

Voyager has a financial runway extending into 2028, ensuring stability for ongoing projects.

What diseases are VY7523 and VY1706 targeting?

Both VY7523 and VY1706 are in clinical trials targeting Alzheimer's disease.

ShareAdd on Google
Tags: VYGR Viatris Investor Conferences Healthcare Alzheimer's clinical trials financial results biotechnology
Last updated: Aug 6, 2026

Biotech snapshot

Cash runway
$172M liquidity · $11M/mo burn
~12 mo
Low dilution risk
Lead asset
VP4896Phase 3
Alzheimer's Disease →